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INTRODUCTION
DIABETES MELLITUS is a serious global health problem. Arecent study by the World Health Organization esti-
mated that the worldwide prevalence of this disease is ex-
pected to grow from 171 million in 2000 to 366 million by
2030 (142). Roughly 21 million people in the United States
(7%) are afflicted by this disorder, and 54 million are at risk.
Moreover, type 2 diabetes is being diagnosed more frequently
in children and adolescents, particularly in American Indians,
African Americans, and Hispanic/Latino Americans. Twenty
percent of Americans over the age of 60 are diabetic, making
the disease one of the most prevalent disorders in the geriatric
population (3).
Hyperglycemia is the metabolic hallmark of both type 1 and
type 2 diabetes. Type 1, which accounts for 5–10% of all
cases in the United States, develops when the immune system
destroys the pancreatic -cells, drastically decreasing insulin
production. Type 2, which accounts for 90% of cases, is a
complex, multisystem disease characterized by both insulin
resistance in insulin-sensitive tissues (skeletal muscle, liver,
and adipose tissue) and progressive pancreatic -cell dys-
function. These deficits ultimately result in too little insulin
to maintain blood glucose levels in the normal range.
Both type 1 and type 2 diabetes markedly increase the risk of
microvascular and macrovascular complications. Microvascu-
lar complications, which center on dysfunction in the capillary
bed of tissues, are wide-ranging, and include the retinopathy,
nephropathy, and neuropathy that eventually affect nearly all
patients with diabetes. Diabetic retinopathy is the major cause
of adult blindness in the United States. Diabetic neuropathy,
which affects roughly half of all diabetic patients is the most
common cause of nontraumatic amputations (38) and diabetic
nephropathy is the major cause of end-stage renal disease (24).
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Obesity, metabolic syndrome, and diabetes are increasingly prevalent in Western society, and they markedly
increase the risk for atherosclerotic vascular disease, the major cause of death in diabetics. Although recent
evidence suggests a causal role for oxidative stress in insulin resistance, diabetes, and atherosclerosis, there is
considerable controversy regarding its nature, magnitude, and underlying mechanisms. Glucose promotes
glycoxidation reactions in vitro, and products of glycoxidation and lipoxidation are elevated in plasma and
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stress are poorly understood. This review focuses on molecular mechanisms of increased oxidative stress in
diabetes, the relationship of oxidant production to hyperglycemia, and the potential interaction of reactive
carbonyls and lipids in oxidant generation. Using highly sensitive and specific gas chromatography–mass
spectrometry, molecular signatures of specific oxidation pathways were identified in tissues of diabetic humans
and animals. These studies support the hypothesis that unique reactive intermediates generated in localized
microenvironments of vulnerable tissues promote diabetic damage. Therapies interrupting these reactive
pathways in vascular tissue might help prevent cardiovascular disease in this high-risk population. Antioxid.
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Macrovascular complications due to atherosclerosis remain
the leading cause of death in diabetic humans. Myocardial
infarction, stroke, and peripheral vascular disease are two to
four times more prevalent in such patients (24). Moreover,
atherosclerosis occurs earlier, and follows a more aggressive
course (45). Thus, the cardiovascular event rate in diabetic pa-
tients without documented coronary artery disease (CAD) is
equivalent to that of nondiabetic patients with CAD
(45, 46). Moreover, diabetic patients have higher mortality
following myocardial infarction than nondiabetic subjects (45).
Women with diabetes lose their premenopausal cardioprotec-
tion, and are vulnerable to CAD at the same rate as men (62).
Whereas tissue-specific factors may accentuate diabetic
damage, it has become increasingly clear that microvascular
and macrovascular diseases share a common pathophysiol-
ogy. During the past two decades, considerable evidence has
implicated oxidative stress in several distinct conditions, in-
cluding aging, atherosclerosis, neurodegenerative diseases,
diabetes, and end-stage renal disease (reviewed in Refs. 4, 5,
15, 56, 72, 123) Oxidative stress occurs when there is an
imbalance in the relative rates of oxidant generation and
oxidant scavenging, with a subsequent increase in the level of
oxidized biomolecules and associated tissue damage.
Accumulating evidence points to hyperglycemia-induced
increases in the production of oxidants and other reactive
intermediates as one important mechanism for the initiation
and progression of endothelial dysfunction in diabetic
subjects (16, 61). Recent advances in our understanding of
oxidative stress, insulin resistance, and diabetes have focused
on mass spectrometric identification of oxidative modifica-
tions to tissue proteins and lipids, characterization of redox
signaling pathways that are activated by oxidative stress and
diabetes, the central role for oxidative stress in all forms of
insulin resistance (61), identification of specific cellular
organelles (such as mitochondria) and enzymes (such as
myeloperoxidase) that generate reactive intermediates, and
the discovery that oxidants can activate apoptotic pathways.
In this review, we discuss the proposal that oxidative stress
might play a causal role in both atherosclerosis and diabetes,
and consider how glucose-induced oxidative stress may lead
to microvascular and cardiovascular complications. We will
also cover the potential relationship of hyperglycemia and
lipids to oxidant-generating pathways and the rationale for
therapies aimed at decreasing oxidative stress. One key issue
has been to identify specific oxidative pathways that contribute
to diabetic complications. Our overall strategy has been to de-
velop sensitive and specific mass spectrometric methods for
defining molecular fingerprints of oxidative pathways in vitro
and, using those tools, to collect evidence that those pathways
are pathophysiologically relevant in vivo. This is a critical pre-




Inflammation, oxidative stress, and atherosclerosis
Atherosclerosis is a chronic inflammatory disease charac-
terized by infiltration of lipids and inflammatory cells, such
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as monocyte-derived macrophages and T-lymphocytes, into
the artery wall (117). Although it is well known that elevated
levels of low-density lipoprotein (LDL) greatly increase the
risk for atherosclerosis (14), in vitro studies suggest that LDL
by itself is not atherogenic but needs to be modified to initiate
atherosclerotic disease (42, 144). This conclusion led to the
‘oxidation hypothesis’, which proposed that LDL must be ox-
idatively modified to become atherogenic. Many lines of evi-
dence support this hypothesis. Oxidized LDL is taken up by
scavenger receptors of macrophages, which then become
lipid-laden foam cells, the pathologic hallmark of early ather-
osclerotic lesions (129). Oxidized LDL has been isolated
from human and animal atherosclerotic tissue, and immuno-
histochemical studies have detected oxidized lipids in athero-
sclerotic lesions (44, 146, 147). All major cell types involved
in atherosclerosis—smooth muscle cells, endothelial cells,
and macrophages—produce reactive oxidants that can oxi-
dize LDL in vitro (59, 96, 130). Moreover, oxidized LDL at-
tracts mononuclear cells and stimulates the production of
monocyte chemoattractant protein-1 and other inflammatory
cytokines, leading to the conversion of fatty streaks to more
advanced complex lesions as smooth muscle cells migrate
from the media into the subendothelial space. Oxidized LDL
may also stimulate smooth cells to synthesize extracellular
matrix and activate a signaling cascade by interacting with
the lectin-like OxLDL receptor (41, 129). Finally, several
structurally unrelated lipid-soluble antioxidants that inhibit
LDL oxidation in vitro also inhibit atherosclerosis in hyperc-
holesterolemic animals (22, 76, 106).
Hyperglycemia and diabetic complications
Both the degree of glycemic control and the duration of
diabetes predict the risk of diabetic complications (79, 98).
These observations have given rise to the “glucose hypothe-
sis,” which suggests that glucose mediates many of the dele-
terious effects of the disease. Both the Diabetes Control and
Complications Trial (DCCT) and the United Kingdom
Prospective Diabetes Study (UKPDS) found that strict
glycemic control dramatically lowered the incidence of
retinopathy, nephropathy, and neuropathy (29, 98, 133, 134).
The majority of patients involved in the DCCT trial were
subsequently followed up in the Epidemiology of Diabetes
Interventions and Complications (EDIC) study. Glycemic
control in the intensive treatment group and the conventional
therapy group were similar during the EDIC follow-up. In-
terestingly, the DCCT/EDIC study demonstrated that a
period of intensive diabetes therapy during the DCCT had
a long-term, beneficial effect on the subsequent risk of
microvascular complications (30). The pathophysiological
mechanisms responsible for the improvement are unclear and
are referred to as “metabolic memory.”
Diabetes also strongly increases the risk for atherosclerotic
macrovascular disease, which is two to four times more com-
mon in diabetic men than in the general population and is
prevalent even in premenopausal diabetic women. Recent
data from the DCCT/EDIC cohort showed that, during the
mean 17 years of follow-up, only 46 cardiovascular events oc-
curred in 31 patients who had received intensive treatment in
the DCCT, compared with 98 events in 52 patients who had
received conventional treatment. Intensive treatment reduced
the risk of any CAD event by 42% and the risk of nonfatal
myocardial infarction, stroke, or death from CAD by 57%,
strongly suggesting that glycemic control lowers macrovascu-
lar disease end points as well (99). Additionally, intensive
therapy during the DCCT associated with decreased progres-
sion of intima—medial thickness, a surrogate marker for ath-
erosclerosis, 6 years after the end of the trial (100). The
UKPDS suggested a trend toward less macrovascular disease
with glucose-lowering therapy, but the difference did not
reach statistical significance.
These findings suggest that hyperglycemia promotes ath-
erosclerosis and its associated complications. Therefore,
glucose itself may be toxic to the artery wall. However,
strict glycemic control alone does not prevent diabetic com-
plications, suggesting the involvement of additional factors.
Proposed factors include abnormalities in lipoproteins, meta-
bolic derangements (insulin resistance, elevated free fatty
acid levels, etc.), and variations in genes controlling lipid me-
tabolism, all of which might be important in macrovascular as
well as microvascular disease (122). Moreover, the presence
of nephropathy, as measured by microalbuminuria and albu-
minuria, associated with a significant increase in the risk of
CAD in the DCCT/EDIC cohort, suggesting common patho-
physiological mechanisms in microvascular and macrovascu-
lar disease (99).
How does hyperglycemia lead to 
diabetic complications?
Several mechanisms have been proposed to explain how
hyperglycemia mediates diabetic damage. They include for-
mation of advanced glycosylation end products (AGEs) (5, 6,
15, 16, 20, 120, 131), oxidative stress (5, 6, 95), carbonyl
stress (5, 6, 95), increased protein kinase C (PKC) activity
(70), altered growth factor or cytokine activities (112, 124),
reductive stress or pseudohypoxia (67, 143), and mitochondr-
ial dysfunction (16, 101). Some of these hypotheses overlap.
For example, AGEs might promote growth factor expression
and oxidative stress, and oxidative stress might promote AGE
formation (5, 6, 95). Mitochondrial superoxide can result in
oxidative stress, form AGE products, and increase PKC activ-
ity (16). It is likely that different tissues are differentially vul-
nerable to hyperglycemia, depending on which biochemical
pathways are affected.
Insulin resistance, visceral adiposity, and CAD
Obesity and visceral adiposity frequently associate with
diabetes and insulin resistance. Also, insulin resistance clus-
ters with the metabolic syndrome, a constellation of classic
CAD risk factors such as lipid abnormalities, hypertension,
and impaired glucose tolerance. Emerging data support the
hypothesis that oxidative stress plays a causal role in insulin
resistance (61) and might be linked with visceral adiposity.
Mature adipocytes function as an endocrine/paracrine organ
that secretes numerous adipokines, cytokines, and growth
factors, particularly in the setting of insulin resistance. A sig-
nificant number of these proatherogenic factors can be re-
leased from components of visceral fat, such as infiltrating
macrophages, that are not adipocytes (139, 140). Several pos-
sible mechanisms link obesity to CAD, such as the increased
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levels of nonesterified fatty acids (NEFA) that result from in-
creased lipolysis and disturbances in adipokine and cytokine
secretion. These processes in turn are linked with insulin re-
sistance (135). NEFAs are independently associated with
CAD mortality in older men (113). Several adipokines and
cytokines, such as adiponectin, interleukin-6 (IL-6), retinol-
binding protein-4 (RBP-4), resistin, and tumor necrosis fac-
tor-, are associated with insulin resistance. RBP-4 is an
adipocyte-derived molecule that is elevated prior to the onset
of diabetes (43), and it appears to impair insulin signaling in
muscle and promote insulin resistance (1, 145). Visceral fat
releases IL-6, which can contribute to local and systemic in-
flammation and elevation of C-reactive protein levels (135).
Thus, insulin resistance is intricately linked with visceral adi-
posity and oxidative stress, and it may promote endothelial
dysfunction and CAD.
OXIDATIVE STRESS IN DIABETES AND
ATHEROSCLEROSIS
Oxidative damage in diabetes and atherosclerosis
Although oxidative stress has a well-established role in di-
abetic complications and atherosclerosis, its origins, magni-
tude, and localization are controversial. Moreover, it is not
known whether oxidative stress is a primary event that occurs
early in the disease or whether it represents a secondary phe-
nomenon that merely reflects end-stage tissue damage (6).
This distinction has important clinical relevance. If oxidative
stress simply reflects tissue damage, interventions that reduce
it may fail to affect the disease process. If oxidative stress
promotes tissue injury, therapies that interrupt oxidative path-
ways early in the disease may prevent complications, and
those that act later may slow disease progression.
Mass spectrometry is a powerful approach for
detecting biomarkers of oxidative stress in vivo
Immunohistochemistry and dihydroethidium fluorescence
have been extensively used to study oxidation-specific epi-
topes and oxidant production in targets of diabetic damage
and atherosclerosis. These techniques are highly sensitive, and
their ability to provide structural data can localize oxidative
events. However, they are nonspecific and, at best, only semi-
quantitative. In contrast, mass spectrometry (MS) offers a
powerful set of analytical tools for quantifying and identifying
biomolecules. Isotope dilution gas chromatography (GC)/MS
is a highly sensitive and specific method that we have used to
quantify oxidation of specific amino acid markers.
The overall strategy for identifying target analytes by
GC/MS is outlined in Fig. 1 (55). Biomolecules such as oxi-
dized amino acids (Fig. 2) derived from plasma or tissue are
separated by GC, derivatized and ionized. The mass-to-charge
ratios of ions derived by fragmenting the ionized, derivatized
parent compound are determined by MS. A full scan mass
spectrum obtained for a target analyte, 3-chlorotyrosine
(derived by acid hydrolysis from plasma proteins), is shown
in Fig. 1. Such a spectrum can unequivocally identify a target
biomolecule because each compound has a unique fragmenta-
tion pattern. The analyte is quantified by adding a stable,
isotopically labeled internal standard, which is identical to
the target analyte except for the heavy isotope. With certain
ionization processes, such as electron capture negative-ion
chemical ionization, it is possible to detect and quantify sub-
femtomole levels of biomolecules.
Pathways for generating oxidants
Many pathways oxidize proteins in vitro. However, the
specific pathways that promote oxidative stress in diabetes
have not been conclusively identified. One reason is that oxi-
dizing intermediates are difficult to detect in vivo because
they are short-lived and generated at low levels. Proposed
pathways for increased oxidant generation and oxidative
stress in diabetes are outlined in Fig. 3.
The glycoxidation pathway. Collectively, glucose-
mediated oxidative reactions are called glycoxidation pathways.
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In its open-chain form, glucose has a carbonyl group that
can be involved in oxidative chemistry. In the presence
of oxygen, glucose can auto-oxidize to reactive oxygen
species, such as hydroxyl radical, which cross-links proteins
(65). Glucose also reacts nonenzymatically with proteins to
form the reversible Schiff base adduct, which subsequently
can rearrange itself into the stable Amadori product and
AGE products.
In vitro, free metal ions catalyze steps in a nonenzymatic
glycoxidation pathway that generates AGE products. One im-
portant intermediate is hydroxyl radical, which can peroxi-
dize lipids and convert phenylalanine residues of proteins
into two unnatural isomers of tyrosine, ortho-tyrosine and
meta-tyrosine (63, 64, 73). Reduced, redox-active metal ions
(Mn+) such as Fe2+ and Cu1+ generate hydroxyl radical (HO•)
when they react with hydrogen peroxide (H2O2; Equation 1).
Mn+ + H2O2 r M
n+ –1 + HO• + HO– (Eq. 1)
FIG. 1. Schematic representation of gas
chromatography–mass spectrometry (GC/
MS) for identifying oxidized amino acids.
This mass spectrum derived from the di-
methylsilyl derivative of 3-chlorotyrosine in
protein digests of human plasma is a represen-
tative example. Plasma proteins were delipi-
dated and hydrolyzed. Isolated amino acids
were derivatized and analyzed by GC/MS.
FIG. 2. Proposed oxidation products
of protein-bound aromatic amino
acids by myeloperoxidase, tyrosyl
radical, glycoxidation/hydroxyl radi-
cal, and reactive nitrogen species
(RNS). Myeloperoxidase converts
tyrosine to 3-chlorotyrosine; tyrosyl
radical cross-links tyrosine to form
o,o´-dityrosine; RNS convert tyrosine
to 3-nitrotyrosine; hydroxyl radical pro-
duces ortho-tyrosine and meta-tyrosine
from phenylalanine.
AGEs can damage tissues through a number of mecha-
nisms, including generation of oxidizing intermediates, for-
mation of immune complexes, interaction with a cellular
receptor called RAGE (Receptor for AGE), and promotion of
cytokine release (5, 131). Although RAGE binds to AGE-
modified proteins in vitro with high affinity, its ligands in
vivo are unclear. High levels of AGEs accumulate in renal
failure, even in nondiabetic patients, and this process reverses
after renal transplantation, implicating the kidneys in AGE
production and/or clearance (6, 92–94).
Many studies have shown that age-adjusted levels of pentosi-
dine and N-carboxymethyllysine (CML), two widely investi-
gated AGE products, correlate with the development of diabetic
complications (34, 63, 89, 95, 121). Thus, glycoxidation reac-
tions can be one mechanism for diabetic complications.
The reactive nitrogen pathway. Another pathway for
generating oxidants involves nitric oxide (NO), which is pro-
duced by endothelial cells to regulate vascular tone. NO is also
produced during inflammation by macrophages, which are early
components of atherosclerotic lesions. NO reacts with superox-
ide (O2
•–) to generate peroxynitrite (ONOO–; Equation 2), a
potent oxidant that converts tyrosine residues to 3-nitrotyrosine.
O2
•– + NO• r ONOO– (Eq. 2)
Thus, 3-nitrotyrosine is a marker for the reactive nitrogen
pathway. It has been detected in low-density and high-density
lipoproteins (LDL and HDL) isolated from human diabetic
atherosclerotic lesions (83, 84, 107), and plasma nitrotyro-
sine levels are elevated in patients with CAD (125, 126).
Because acute hyperglycemia promotes vasodilation in humans,
glucose might directly or indirectly enhance NO release and
oxidant generation (122).
The myeloperoxidase pathway. The major path-
way through which macrophages and other phagocytic cells of
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the innate immune system generate oxidants begins with the
cells’ membrane-bound NADPH oxidase (NOX), which pro-
duces superoxide (Equation 3).
NADPH + 2 O2 r NADP
+ + H+ + 2 O2
•– (Eq. 3)
Superoxide dismutates into hydrogen peroxide (Equation 4).
2 H+ + 2 O2
•– r H2O2 + O2 (Eq. 4)
The peroxide can be used by another phagocyte enzyme,
myeloperoxidase (77, 78), to convert chloride ion to
hypochlorous acid (Equation 5).
H2O2 + Cl
– + H+ r HOCl + H2O (Eq. 5)
Oxidation of NO with oxygen yields nitrite (NO2
–), which
myeloperoxidase converts to nitrogen dioxide radical (NO2
•;
Equation 6), a potent nitrating intermediate (37, 40).
NO2
– + H2O2 r NO2
• + H2O (Eq. 6)
Reactive nitrogen species, including peroxynitrite and
NO2
•, might contribute to the inflammatory process by nitrat-
ing lipoproteins and other biomolecules.
Hyperglycemia can activate PKC (70, 71, 75), which leads
to phagocyte activation, secretion of myeloperoxidase, and
oxidant generation. NEFAs that commonly are overabundant
in diabetes can also activate phagocytes in vitro. These
changes might enhance the production of superoxide and hy-
drogen peroxide, which myeloperoxidase converts into more
potent cytotoxic oxidants, such as hypochlorous acid and ni-
trogen dioxide radical.
The mitochondrial pathway. Mitochondrial elec-
tron transport generates superoxide. Glucose promotes mito-
chondrial electron transport in cells, and a glucose-driven
mitochondrial oxidation pathway has been proposed as one
FIG. 3. Potential pathways for
increased oxidant generation
in diabetes and atherosclerosis.
AGE, advanced glycosylation
end-products; eNOS, endothelial
nitric oxide synthase; MPO,
myeloperoxidase.
mechanism for damaging cells in diabetes (16). When cultured
endothelial cells are exposed to high levels of glucose, their
mitochondria increase their superoxide output (33). Endothe-
lial cells transfected with mitochondrial superoxide dismutase,
a scavenger of superoxide, do not show this response. Thus, su-
peroxide production by the mitochondrial electron transport
chain could be one mechanism for diabetic tissue damage (16,
101). The mitochondrial pathway can be blocked by inhibitors
of oxidative phosphorylation (16) or by a superoxide dismutase
mimic (118).
Mitochondrial superoxide overproduction mediated by
hyperglycemia might also increase polyol pathway activity,
PKC activity, and hexosamine flux, resulting in cellular
dysfunction and tissue damage (16). Moreover, superoxide
inhibits glyceraldehyde phosphate dehydrogenase, a key gly-
colytic enzyme whose inactivity could make upstream
metabolites accumulate. Such inhibition of glycolysis might
promote end-organ damage by diverting metabolites into
the hexosamine pathway or stimulating the polyol and diacyl-
glycerol-PKC pathways. Benfotiamine, a lipid-soluble thiamine
analog that inhibits these pathways by activating transketo-
lase, an enzyme in the pentose pathway shunt, can prevent
complications from experimental diabetes in animal
models (48).
Endothelial cell dysfunction and excess super-
oxide production. Endothelial dysfunction has been pro-
posed to generate excess superoxide, resulting in oxidative
stress. Two enzymes have been implicated: NOX and uncou-
pled endothelial NO synthase (eNOS). Glucose and NEFAs
can directly stimulate NOX because they activate PKC (69).
Apocynin, which inhibits both NOX and PKC, reduced vascu-
lar superoxide generation in an animal model of type 1 diabetes
and two models of type 2 diabetes (obese ob/ob mice and
Zucker fatty rats) (23, 128). Additionally, it has been demon-
strated that AGEs (138), oxidized LDL (72), and angiotensin II
(25) can also increase NOX activity. Angiotensin II may repre-
sent a pathophysiologically relevant pathway for stimulating
the production of reactive intermediates by artery wall cells be-
cause inhibitors of this pathway lower the risk for cardiovascu-
lar events in diabetics (60).
Oxidation of tetrahydrobiopterin, the reduced form of
biopterin that is required for arginine reduction and
NO production by eNOS, uncouples eNOS from NO syn-
thesis. Under these conditions, eNOS transfers electrons to
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molecular oxygen to generate superoxide (136). An alterna-
tive mechanism for uncoupling eNOS involves angiotensin II,
which can induce dihydrofolate reductase deficiency, perhaps
via a hydrogen peroxide-dependent mechanism. Because di-
hydrofolate reductase maintains tetrahydrobiopterin in its re-
duced form, dihydrofolate reductase deficiency results in
eNOS uncoupling (25). Recently, it has been demonstrated
that attenuation of angiotensin II signaling can recouple
eNOS and inhibit peroxide production by NOX in diabetic
mice (102).
The glucose-polyunsaturated fatty acid (PUFA)
pathway. To determine whether glucose can generate reac-
tive intermediates by interacting with polyunsaturated fatty
acids, we incubated it with LDL or a model protein, RNase
(109). The buffer was free of redox-active metal ions because it
had been treated with Chelex resin and supplemented with a
metal chelator. Under these conditions, pathophysiologically
relevant concentrations of glucose modified LDL, as evidenced
by the formation of oxidized amino acids, even though metal
ions were absent (Fig. 4). In striking contrast, glucose exposure
did not increase levels of oxidized amino acids in RNase. These
observations suggest that glucose promotes LDL oxidation
because the particle contains lipid as well as protein. Our obser-
vation that levels of lipid oxidation products rise when LDL is
exposed to glucose is consistent with this proposal.
To test the hypothesis that lipid can enhance protein oxida-
tion, we incubated RNase with saturated, monounsaturated, or
PUFA (Fig. 5). Glucose stimulated protein oxidation only in
the presence of a PUFA. Thus, glucose appears to promote
protein oxidation by a pathway involving peroxidation of
PUFAs as this reaction is inhibited by lipid-soluble antioxi-
dants (109).
To determine whether glucose’s carbonyl group promotes
LDL oxidation, we replaced glucose with a variety of short-
chain and phosphorylated sugars that have highly reactive
carbonyl groups (109). All of the carbonyl compounds pro-
moted oxidation of LDL (but not RNASe) protein more effec-
tively than did glucose. In contrast, LDL oxidation was not
enhanced by sorbitol, the reduced form of glucose that lacks a
carbonyl moiety (Fig. 6). Collectively, these observations in-
dicate that glucose can generate a species resembling the hy-
droxyl radical by a carbonyl/PUFA pathway. This pathway
might therefore promote localized oxidative stress in tissues
vulnerable to diabetic damage (109).
FIG. 4. Product yields of ortho-tyrosine,
meta-tyrosine, o,o´-dityrosine, and 3-
nitrotyrosine in LDL and RNase exposed to
D-glucose in vitro. LDL and RNase (1 mg
protein/ml of buffer) were incubated with 0
mM (Control) or 25 mM D-glucose. At the end
of the incubation, amino acids in the protein
were quantified by GC/MS. *p < 0.05 by Stu-
dent’s t-test. Reproduced from (109).
OXIDIZED AMINO ACIDS SERVE AS
MOLECULAR FINGERPRINTS FOR
SPECIFIC OXIDATION PATHWAYS
The examples given above illustrate that many different
pathways can oxidize lipoproteins in vitro. To understand the
molecular mechanisms that promote oxidative stress in vivo,
we first used a chemical approach to define the patterns of
oxidation products that are formed by well-characterized oxi-
dant-generating systems in vitro. Then we looked for similar
patterns in tissue and plasma. We focused on proteins because
aromatic amino acids retain the initial footprint of the reac-
tive intermediate that initiates oxidative damage. In contrast,
lipid peroxidation products readily undergo subsequent
chain-propagating reactions, which mask the products
formed early in the pathway. Moreover, many different
OXIDATIVE STRESS IN DIABETES 961
oxidizing intermediates give the same spectrum of oxidized
lipids, making it difficult to identify specific pathways that
trigger lipid oxidation.
Oxidizing intermediates are difficult to detect in vivo be-
cause they are short-lived and generated at low levels. To
sidestep this problem, we and others have identified and are
able to monitor acid-stable products of protein oxidation,
both in vitro and in vivo (2, 5, 7–9, 12, 13, 37, 51, 56, 57,
80–84, 107–111). Our overall approach is to use isotope dilu-
tion GC/MS to accurately identify oxidized amino acids iso-
lated from tissue proteins. These markers, which include
ortho-tyrosine, meta-tyrosine, dityrosine, 3-nitrotyrosine,
and 3-chlorotyrosine (Fig. 2), indicate which biochemical
pathway has damaged a protein.
Evidence for localized oxidative 
stress in diabetes
Indirect evidence supports the hypothesis that oxidative
stress increases in diabetes. For example, numerous investi-
gators have reported elevated levels of products of lipid,
protein, and nucleic acid oxidation in the blood of diabetic
patients, though most of these products were monitored with
nonspecific assays that may not yield valid results with com-
plex biological material (6). Studies using sensitive and spe-
cific MS methods to quantify oxidation products have cast
doubt on the concept of a generalized increase in oxidative
stress in diabetic humans. For example, Wells–Knecht et al.
(141) performed careful, quantitative studies on collagen, a
long-lived protein that is freely exposed to blood glucose and
lipids. They concluded that diabetes does not enhance oxida-
tive stress because collagen from diabetic and euglycemic
subjects contained similar age-adjusted levels of ortho-tyrosine
and methionine sulfoxide, two well-characterized markers of
protein oxidation in vitro. Other mass spectrometric studies
have failed to find differing levels of glycoxidation products
in urine and blood of diabetic and euglycemic humans (6, 35).
These observations argue strongly against a generalized
FIG. 5. Reaction requirements for oxidation of RNase by
D-glucose. RNase was incubated in buffer with and/or with-
out 25 mM of fatty acid (stearate, 18:0; oleate, 18:1; linoleate,
18:2; linolenate, 18:3; arachidonate, 20:4) and/or 25 mM
D-glucose. At the end of the incubation, amino acids in the pro-
tein were quantified by GC/MS. *p < 0.05 by Student’s t-test.
Reproduced from (109).
FIG. 6. Quantification of ortho-tyrosine in LDL and RNase incubated with reactive carbonyl compounds and sorbitol.
LDL or RNase was incubated in buffer supplemented with 25 mM of the indicated sugar for 15 days at 37°C. At the end of the in-
cubation, amino acids in the proteins were quantified by GC/MS. *p < 0.05 by Student’s t-test. Reproduced from (109).
increase in oxidative stress in diabetes, at least in the extra-
cellular compartment. None of the above studies excluded the
possibility of localized, tissue-specific increases in oxidative
stress in organs vulnerable to diabetic damage: the retina,
kidney, vascular wall, and peripheral nerve tissue.
MS quantitation of oxidized amino acids in aortic
proteins of diabetic Cynomolgus monkeys reveals
localized oxidative damage by hydroxyl radical
To investigate the potential role of localized oxidative
stress in diabetic macrovascular disease, we used a primate
model of diabetic atherosclerosis. These studies involved
Cynomolgus monkeys that had been hyperglycemic for
6 months due to streptozotocin-induced diabetes (111). We
analyzed samples from 7 controls and 8 diabetic Cynomolgus
monkeys, sampling three different areas from the thoracic
aorta of each animal. Compared with the control samples, the
aorta wall proteins from the diabetic animals showed a signif-
icant 40% increase in ortho-tyrosine (Fig. 7A) and a similar
(60%) increase in meta-tyrosine (Fig. 7B). In vitro studies
identify these oxidized amino acids as products of hydroxyl
radical, implicating a hydroxyl radical-like species in damage
to artery wall proteins in diabetic monkeys.
The concentration of o,o´-dityrosine, a marker of tyrosyl
radical that is produced in lower yield by hydroxyl radical
(Fig. 7C), was fourfold greater in the diabetic samples than in
the control samples. Thus, ortho-tyrosine, meta-tyrosine, and
o,o´-dityrosine levels were higher in aortic proteins from dia-
betic monkeys than in those from control animals. However,
we found no significant difference in 3-nitrotyrosine levels in
proteins isolated from aortic tissue of control and diabetic
Cynomolgus monkeys (Fig. 7D). Collectively, these results in-
dicate that ortho-tyrosine, meta-tyrosine, and o,o´-dityrosine
levels are selectively elevated in aortic proteins of diabetic
monkeys, whereas 3-nitrotyrosine levels remain unchanged.
This pattern of oxidized amino acids suggests that a
hydroxyl-radical like oxidant promotes aortic damage in this
animal model of type 1 diabetes.
Correlations between aortic tissue levels of the
oxidized amino acids and serum levels of 
glycated hemoglobin
To determine whether glucose promotes protein oxidation
in vivo, we assessed the relationship between level of
glycemic control (measured as serum glycated hemoglobin)
and levels of amino acid oxidation products in aortic tissue
in control and diabetic Cynomolgus monkeys (Fig. 8). Linear
regression analysis demonstrated a strong correlation be-
tween levels of both ortho-tyrosine and meta-tyrosine and
glycated hemoglobin (r2 = 0.9 and 0.8, respectively; both p <
0.001). Levels of o,o´-dityrosine and glycated hemoglobin
correlated less strongly (r2 = 0.3; p = 0.07). In contrast, there
was no correlation between levels of 3-nitrotyrosine and gly-
cated hemoglobin. These observations support the hypothe-
sis that glucose promotes the formation of ortho-tyrosine
and meta-tyrosine in the artery wall and suggest that both
glucose and other pathways contribute to the generation of
o,o´-dityrosine (111).
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Plasma and urinary levels of oxidized amino 
acids are potential markers for assessing 
oxidative stress in vivo
There is increasing evidence that oxidized amino acids
in plasma and urine can serve as markers for noninvasive
FIG. 7. Quantification of ortho-tyrosine (a), meta-tyrosine
(b), o,o´-dityrosine (c), and 3-nitrotyrosine (d) in aortic pro-
teins isolated from control and diabetic Cynomolgus mon-
keys. Aortic tissue was harvested from control and diabetic
animals at the end of the 6-month study. Tissue was delipi-
dated, hydrolyzed, and amino acids were quantified by GC/MS.
*p < 0.01 by Student’s t-test. Reproduced from (111).
FIG. 8. Concentrations of ortho-tyrosine (a), meta-tyrosine
(b), o,o´-dityrosine (c), and 3-nitrotyrosine (d) in aortic pro-
teins of Cynomolgus monkeys as a function of glycated hemo-
globin. Lines represent the linear least squares fit of the data.
Glycated hemoglobin was determined in serum of both control
and diabetic animals at the end of the 6-month study. *p < 0.001
by Spearman rank correlation. Reproduced from (111).
assessment of oxidative stress in vivo. Plasma and urinary
levels of these markers are likely to be proportional to the rate
of generation and thus can serve as indices of chronic oxida-
tive stress in vivo (8, 9, 82, 107, 108, 125–127, 150).
To determine whether oxidized amino acids in urine might
serve as markers of oxidative stress, we determined the urinary
excretion of o,o´-dityrosine in a mouse model of peritoneal
inflammation (9). To correct for individual differences in
glomerular filtration, we normalized o,o´-dityrosine levels to
those of urinary creatinine. The concentration of o,o´-dityrosine
was three-fold higher in the urine of mice with active peri-
toneal inflammation, but it failed to increase in mice lacking
phagocytic gp91phox subunit of NOX. These results suggest
that degradation of oxidatively damaged proteins in phago-
cytes releases free o,o´-dityrosine that enters the blood and is
excreted in urine.
These observations may be relevant to human pathophysi-
ology. For example, a case-control study demonstrated that
systemic levels of protein-bound nitrotyrosine were signifi-
cantly higher in patients with CAD than in controls with
healthy arteries. Moreover, statin therapy lowered levels of
oxidation markers in plasma, raising the possibility that these
drugs can potentially be antioxidants (125–127). Therefore,
these markers might serve not only to assess oxidative stress
but also to monitor the efficacy of therapy.
Oxidized HDL is a plasma marker of oxidative
stress in subjects with CAD
Because lipoprotein oxidation is implicated in atherogene-
sis, we analyzed plasma lipoproteins for oxidized amino acids.
Preliminary studies demonstrated that HDL, but not LDL, iso-
lated from plasma of subjects with established CAD contained
high levels of 3-chlorotyrosine, a highly specific marker for the
myeloperoxidase pathway. The level of 3-chlorotyrosine was
13-fold higher in HDL isolated from plasma of subjects with
established CAD than in HDL from plasma of healthy subjects
(Fig. 9); (8). We also found that levels of 3-nitrotyrosine were
twice as high in HDL from plasma of patients with established
CAD (Fig. 10); (107)). These observations raise the exciting
possibility that oxidized HDL might be a novel marker for clin-
ically significant CAD. It will clearly be important to deter-
mine whether levels of oxidized amino acids are elevated in
HDL and LDL of diabetic humans.
Lipoxidation in diabetes mellitus
Several observations suggest a complex interplay among
protein oxidation, lipid peroxidation, and AGE formation.
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When LDL is incubated with glucose or glycated proteins,
lipoprotein oxidation increases (18, 19, 66, 74). Moreover,
CML, an extensively studied AGE, forms from PUFAs dur-
ing lipid peroxidation (39). Thus, CML is a product of both
glycoxidation and lipoxidation. CML and related glycoxida-
tion products can form not only from early intermediates in
the Maillard reaction but also directly from glyoxal or
methylglyoxal, which may in turn be derived from either
carbohydrates or lipids (6). PUFAs are oxidized much more
readily than is glucose, and dyslipidemia is common in dia-
betic patients. Thus, elevated levels of plasma lipoproteins
might contribute to lipoxidation in vivo. AGE lipids have
also been found in diabetic plasma lipoproteins (18, 19,
114–116), and levels of isoprostanes—specific markers
of nonenzymatic lipoxidation—are elevated in diabetic
patients (28, 91). CML and other AGE compounds could
thus originate in vivo when carbohydrates or lipids react
with proteins.
Aminoguanidine and pyridoxamine comprise of a new
class of agents termed “amadorins” that prevent the amadori
product from forming AGEs. Both inhibit AGE formation
from carbohydrates, and pyridoxamine also inhibits advanced
lipoxidation reactions (104, 137). Aminoguanidine prevents
diabetic complications in animal models, which may reflect
its ability to inhibit AGE formation and inducible nitric oxide
synthase (17, 36, 47, 49, 68). Clinical trials were halted, how-
ever, because aminoguanidine proved too toxic to humans.
Pyridoxamine is effective in preventing retinopathy and
nephropathy in diabetic rats (31, 132), but its effects on hu-
mans remain to be determined.
Carbonyl stress in diabetes
Glucose is a reactive carbonyl that can generate additional
carbonyls and other reactive compounds through both enzy-
matic and nonenzymatic reactions. Baynes and Thorpe pro-
posed that diabetes is a characterized by carbonyl stress that
in turn may account for the increased protein and lipid modi-
fications that typify diabetes and uremia (6). In this model,
reactive carbonyl production rises due to increased substrate
stress (elevated levels of glucose and its derivatives), and is
compounded by deficiency or overload of pathways that
detoxify carbonyl compounds. The abundance of reactive
carbonyls enhances protein and lipid modification. Oxidative
stress is thus a primary event that increases carbonyl produc-
tion, but is also a secondary event due to elevated carbonyl
levels (6).
FIG. 9. MS quantification of 
3-chlorotyrosine in HDL iso-
lated from plasma. Plasma
was obtained from healthy con-
trol subjects and subjects with es-
tablished CAD. Oxidized amino
acids isolated from hydrolyzed
HDL proteins were quantified by
GC/MS. p < 0.01 by Student’s t-
test. Reproduced from (8).
FIG. 10. MS quantification of
3-nitrotyrosine in HDL iso-
lated from plasma. Plasma
was obtained from healthy con-
trol subjects and subjects with
established CAD. Oxidized
amino acids isolated from hy-
drolyzed HDL proteins were
quantified by GC/MS *p < 0.01
by Student’s t-test. Reproduced
from (107).
Glucose promotes lipid and protein oxidation in
diabetic retinal tissue by a carbonyl- and PUFA-
dependent pathway
To begin to explore the pathophysiological relevance of
the carbonyl-PUFA pathway, we quantified levels of protein
and lipid oxidation products in the retina of hyperglycemic
Sprague–Dawley rats, a well-characterized model of diabetic
retinopathy (109). Abnormalities such as increased vascular
permeability became well established in retinal tissue as
early as 4 weeks after STZ treatment (85, 149). After 6
weeks, retinal tissue contained markedly elevated levels of
ortho-tyrosine and meta-tyrosine and high levels of hydroxy-
octadecadienoic acid, a major product of lipid oxidation.
Treatment with the carbonyl scavenger aminoguanidine
blocked these changes but failed to affect levels of ortho-
and meta-tyrosine in control animals. We observed no differ-
ences in levels of D-glucose or hemoglobin A1C in the rats on
the two different diets. Thus, glucose or other reactive car-
bonyls that abound in the diabetic milieu promote lipid and
protein oxidation in vivo by a pathway requiring PUFAs.
These observations suggest that glucose might operate lo-
cally by a variety of mechanisms, damaging artery wall pro-
teins even in the absence of generalized oxidative stress. It
will be important to determine whether the pattern of oxida-
tion products in diabetic humans resembles the ones we
observed in the monkey and rat studies.
Hyperlipidemia in concert with hyperglycemia
stimulates the proliferation of macrophages in
atherosclerotic lesions: potential role of 
glucose-oxidized LDL
Macrophage proliferation has been implicated in the pro-
gression of atherosclerosis. Recent studies have investigated
the effects of hyperglycemia and hyperlipidemia on macro-
phage proliferation in murine atherosclerotic lesions and
isolated primary macrophages (80). Glucose promoted lipid
and protein oxidation of LDL in vitro. Oxidation of LDL
with glucose resulted in a selective increase in protein-
bound ortho-tyrosine and meta-tyrosine. Moreover, glucose-
oxidized LDL—but not elevated levels of glucose alone—
stimulated proliferation of isolated macrophages. These
observations may be pertinent to diabetic vascular disease be-
cause macrophage proliferation in atherosclerotic lesions was
observed in LDL receptor-deficient mice that were both hy-
percholesterolemic and hyperglycemic but in not mice that
were only hyperglycemic (80).
Antioxidants for preventing diabetic complications
The proposed role of oxidized LDL in atherogenesis sug-
gests that a high dietary antioxidant intake might prevent pre-
mature vascular disease in humans. However, the majority of
prospective, double-blind, placebo-controlled trials of one
proposed lipid-soluble antioxidant, vitamin E, have failed to
demonstrate any reduction of clinical events in patients with
established atherosclerosis (54). The disappointing results of
these trials have led many to question the role of oxidative
damage in the pathogenesis of coronary artery disease in humans.
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It might be, however, that vitamin E’s ability to serve as an
antioxidant in vivo should be questioned (54). Thus, despite
the impressive ability of other lipid-soluble antioxidants to
block atherosclerosis in hypercholesterolemic animals, vita-
min E—at doses that fail to lower cholesterol levels—has not
exerted a consistent inhibitory effect in such experiments.
These observations (53, 54, 87) emphasize the importance of
documenting that a proposed antioxidant intervention actu-
ally inhibits oxidative reactions in vivo.
There is also remarkably little information about the in-
fluence of vitamin E supplementation on lipid oxidation in
humans. Indeed, a recent study of healthy humans taking
dietary supplements as high as 2,000 IU/day for 8 weeks
found no change in levels of three lipid oxidation products:
4-hydroxynonenal and two isoprostanes (90). The investiga-
tors assessed products of lipid peroxidation using GC/MS, a
sensitive and specific method. These results strongly sug-
gest that vitamin E failed to inhibit lipid peroxidation in
these individuals.
We have shown that one pathway for LDL oxidation in the
human artery wall involves myeloperoxidase (27, 55). It is
therefore noteworthy that vitamin E also fails to inhibit many
of the reactions executed by that enzyme, that myeloperoxi-
dase and its characteristic products are found at high levels
in human atherosclerotic tissue, and that myeloperoxidase
oxidizes LDL by reactions that are independent of lipid per-
oxidation (50, 52, 58, 119). These observations highlight the
importance of identifying both the targets of oxidation in the
artery wall and the biochemical pathways that promote oxida-
tive reactions in vivo, using sensitive and specific analytical
techniques such as MS.
Trials of antioxidants and carbonyl trapping agents in hu-
mans suffering from diabetes have also yielded discouraging
results. Chronic treatment with vitamin E failed to decrease
cardiovascular events in a large study that included a high
percentage of diabetic patients (148). One possible reason
is that antioxidant therapy might benefit only subjects who
exhibit increased oxidative stress. Indeed, the renal failure
patients who benefited from vitamin E therapy (10) might
have been a subset with greatly increased carbonyl and oxida-
tive stress (94).
Certain inhibitors of oxidant generation and proposed
antioxidants have shown promise in preliminary studies of di-
abetic neuropathy. These include the xanthine oxidase in-
hibitor, allopurinol, and the chain-breaking antioxidant
alpha-lipoic acid (ALA). A recent report (21) examined the
effects of allopurinol on endothelial function and oxidative
stress in type 2 diabetic patients. The investigators showed
that allopurinol increased the endothelium-dependent mean
blood flow response to acetylcholine by 30% and decreased
systemic levels of malondialdehyde. However, the relevance
of endothelium-dependent mean blood flow response as a
surrogate marker for cardiovascular disease has been ques-
tioned because this technique predicted that vitamin E would
prevent vascular disease.
ALA is an endogenous free radical scavenger (97, 105) and
metal chelator (105). ALA is reduced metabolically to dihy-
drolipoate, which combines free radical scavenging and metal
chelating properties with the ability to regenerate high con-
centrations of nonenzymatic and enzymatic antioxidants (86,
103, 105). In the Alpha-Lipoic Acid in Diabetic Neuropathy
(ALADIN) Study, neuropathic symptoms lessened in type
2 diabetic subjects treated with intravenous ALA for 3 weeks
(152). In the ALADIN III Study, 509 subjects with type 2 di-
abetes and symptomatic diabetic neuropathy were adminis-
tered sequential treatment with 600 mg/day ALA intra-
venously for 3 weeks followed by 600 mg thrice daily orally
for 6 months. The total symptom score for neuropathy symp-
toms was significantly better at early time points in the ALA-
treated group and neuropathic deficits were consistently
improved throughout the study (151). In the Deutsche Kar-
diale Autonome Neuropathie (DEKAN) Study, heart rate
variability improved after 4 months of oral treatment with
ALA (800 mg/day) in type 2 diabetic patients with neuropa-
thy (153). Whether long-term oral therapy with ALA will be
effective in diabetic neuropathy remains to be established.
The clinical significance of affecting heart rate variability in
diabetics is also unclear.
Pharmacologic agents currently in clinical practice with
demonstrated benefit in CAD may act in part by serving as
antioxidants. Angiotensin converting enzyme (ACE) in-
hibitors and statins have lowered CAD event rates in random-
ized controlled trials in diabetic patients (26, 60). As noted
above, many lines of evidence suggest that angiotensin II
triggers oxidant production by endothelial cells and other
cells of the artery wall. Interestingly, the ACE inhibitor
ramipril slowed the onset of type 2 diabetes in the Heart Out-
comes Prevention Evaluation (HOPE) trial (60), though this
effect was not confirmed in a more recent trial (11).
Ramipril’s well-recognized ability to mitigate the pro-oxidant
effect of angiotensin II may in part account for its efficacy. A
case-control study demonstrated that systemic levels of pro-
tein-bound nitrotyrosine were significantly higher among
patients with CAD and that statin therapy lowered levels of
oxidized amino acids in plasma, raising the possibility that
statins can potentially be antioxidants (125–127). Thiazo-
lidinediones (TZD), which have been proposed to improve
endothelial dysfunction in part by decreasing oxidative stress
via activation of the peroxisome-proliferator-activated recep-
tor , have now been shown to decrease carotid intimal thick-
ness in diabetic subjects independently of their ability to
boost glycemic control (88). Additionally, TZD treatment
also decreased progression to overt diabetes in subjects with
impaired glucose tolerance (32). The oxidative pathways
modulated by these agents have not been defined and should
be the focus of future investigations.
CONCLUSIONS AND PERSPECTIVES
The ability to accurately quantify amino acid oxidation
markers in tissue samples, plasma, and urine can provide in-
valuable mechanistic insights into disease pathogenesis.
Therefore, further studies of the biochemical basis for oxidant
generation might facilitate the development of specific antiox-
idant therapies designed to retard diabetic complications.
The potential role of antioxidant therapies in preventing
microvascular and macrovascular disease in diabetic humans
is another important issue. To examine the oxidative stress
hypothesis in diabetes, suitable test subjects and optimal an-
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tioxidant regimens need to be identified. Such a trial should
involve diabetic patients with evidence of increased oxida-
tive stress (for example, subjects with elevated levels of oxi-
dized amino acids in their plasma or urine). These high-risk
individuals are most likely to benefit from antioxidant ther-
apy. The optimal regimen for inhibiting oxidative tissue
injury in humans also needs to be determined so that test
compounds can be administered in effective antioxidant
regimens.
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